Vytrus Biotech Expands with New Plant After 200% Stock Surge

With a stock market rise of almost 200% so far this year, Vytrus Biotech is gaining the structure to accelerate its expansion plans.

The Terrassa, Barcelona-based company aims to achieve revenues of 12 million by 2027 and, to achieve this, needs to expand its production capacity. Therefore, Vytrus Biotech will open a new production plant to meet the manufacturing requirements that the projected growth entails.

The Catalan cosmetics Vytrus Biotech plans a new production facility to boost capacity and reach €12 million in revenue by 2027

Vytrus Biotech explains that it has signed a new lease agreement for an industrial warehouse to be used for “the installation of a new production plant.” “This transaction is part of the company’s expansion and growth plan, aimed at strengthening its production capacity and meeting emerging market needs,” it states.

The listed company dedicated to the cosmetics sector explains that in 2025 it will “inaugurate a new cycle of capacity expansion.” In addition to the new factory, the company reports it has invested €0.33 million in Capex in the first half of the year, with new production equipment and a laboratory. The group’s facilities in Catalonia currently cover 1,700 square meters and are used for production, R&D, warehouses, and corporate offices. The new facility will also be located in the region.

The Barcelona-based biotech accelerates growth with a new factory to meet soaring demand and sustain its strong market momentum

This would strengthen Vytrus Biotech’s momentum on its path to achieving the €12 million in sales and €5 million in EBITDA reported in the 2024-2027 strategic plan. In the first half of 2025, the company achieved sales of €4.38 million, EBITDA of €1.43 million, and profit of €1.33 million

Sales in the European Union, including Spain (+81%), increased by 76% in the period, and in the United States, the increase was 49%. By indication, anti-aging, hair, and brightening products were the best performers in the portfolio.

The Catalan company closed Thursday’s trading session with a 5% increase to €6.25 per share. The increase has reached 189% so far this year and 121% since 2022, when it was listed on the stock exchange. It has been trading continuously since September 8th, compared to the two windows in which it had previously set prices.

__

(Featured image by Logan Armstrong via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in elEconomista.es. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.